Flush with AZ cash, Almirall seeks dermatology assets
This article was originally published in Scrip
Executive Summary
Almirall has fresh funds and wants to spend them on acquiring new dermatology assets, CEO Eduardo Sanchiz said following the surprise announcement that the Spanish firm is to sell its respiratory portfolio to AstraZeneca.
You may also be interested in...
Interview: Almirall CEO Guenter Plots 'Play To Win' Future
Peter Guenter has steadied the ship at Almirall, and after seven months in the role he outlines his vision for the company in his first exclusive interview as CEO of Spain's largest pharma company.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.